(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.21%) $0.928
(0.17%) $10.86
(0.00%) $0.792
(-0.29%) $92.31
Live Chart Being Loaded With Signals
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally...
Stats | |
---|---|
Today's Volume | 31 473.00 |
Average Volume | 52 936.00 |
Market Cap | 1.59B |
EPS | $0 ( 2024-01-25 ) |
Next earnings date | ( $0.310 ) 2024-05-28 |
Last Dividend | $12.81 ( 2018-12-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.70 |
ATR14 | $0.0330 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Sell | 712 500 | Warrant (right to buy) |
2010-11-04 | Sun Pharmaceutical Industries Ltd | Buy | 5 159 765 | Ordinary Shares |
2010-11-01 | Franklin Resources Inc | Sell | 5 159 765 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 84 transactions |
Buy: 16 575 249 | Sell: 25 681 902 |
Volume Correlation
Taro Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taro Pharmaceutical Correlation - Currency/Commodity
Taro Pharmaceutical Financials
Annual | 2023 |
Revenue: | $572.95M |
Gross Profit: | $268.32M (46.83 %) |
EPS: | $0.680 |
Q4 | 2023 |
Revenue: | $146.59M |
Gross Profit: | $75.71M (51.65 %) |
EPS: | $0.180 |
Q3 | 2023 |
Revenue: | $139.20M |
Gross Profit: | $64.05M (46.01 %) |
EPS: | $0.190 |
Q2 | 2023 |
Revenue: | $130.50M |
Gross Profit: | $46.96M (35.99 %) |
EPS: | $-0.0748 |
Financial Reports:
No articles found.
Taro Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.81 | 2018-12-10 |
Last Dividend | $12.81 | 2018-12-10 |
Next Dividend | $0 | N/A |
Payout Date | 2018-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.22 | -- |
Div. Sustainability Score | 5.86 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 4.03 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $12.81 | 12.40% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend Royal | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0748 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0211 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0261 | 1.500 | -0.821 | -1.231 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.022 | 1.500 | 5.43 | 8.15 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.55 | 1.000 | -2.05 | -2.05 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 8.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.480 | 1.000 | 5.33 | 5.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0360 | 1.000 | -1.280 | -1.280 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.282 | 0.800 | -1.451 | -1.161 | [0.5 - 2] |
Total Score | 5.86 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.82 | 1.000 | 6.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0261 | 2.50 | -0.528 | -1.231 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 9.24 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.768 | 1.500 | -8.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.65 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Taro Pharmaceutical
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators